

NDA 20-771/S-004

Pharmacia & Upjohn Company
Attention: Gregory Shawaryn
Regulatory Manager, Regulatory Affairs
7000 Portage Road
Kalamazoo, MI 49001

06 APR 2001

Dear Mr. Shawaryn:

Please refer to your supplemental new drug application dated December 22, 1999, received December 23, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Detrol (tolterodine tartrate) tablets.

We acknowledge receipt of your submissions dated February 27, March 15 (facsimile), March 20 (facsimile), and April 3, 2001 (facsimile). Your submission of October 26, 2000 constituted a complete response to our October 23, 2000 Approvable action letter.

This supplemental new drug application provides for the use of Detrol (tolterodine tartrate) tablets for the treatment of overactive bladder with symptoms of urgency, frequency and urge urinary incontinence.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted March 20, 2001).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-771/S-004." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and

the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Evelyn R. Farinas, R.Ph., M.G.A., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

Susan Allen, M.D.
Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research